Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab With Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
NCT07454382Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2026
- Primary completion
- Aug 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2026; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07454382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454382.